BEMCX
Price
$14.20
Change
-$0.07 (-0.49%)
Updated
Jun 26 closing price
Net Assets
1.32B
RNWAX
Price
$101.10
Change
-$0.82 (-0.80%)
Updated
Jun 26 closing price
Net Assets
90.88B
Interact to see
Advertisement

BEMCX vs RNWAX

BEMCX vs RNWAX Comparison Chart in %
View a ticker or compare two or three
VS
BEMCX vs. RNWAX commentary
Jun 27, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEMCX is a Hold and RNWAX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RNWAX has more cash in the bank: 90.9B vs. BEMCX (1.32B). BEMCX pays higher dividends than RNWAX: BEMCX (1.31) vs RNWAX (0.49). BEMCX was incepted earlier than RNWAX: BEMCX (13 years) vs RNWAX (24 years). BEMCX (2.07) is less costly to investors than RNWAX (1.66). RNWAX is a more actively managed with annual turnover of: 46.00 vs. BEMCX (1.27). RNWAX has a lower initial minimum investment than BEMCX: RNWAX (250) vs BEMCX (2500). BEMCX annual gain was more profitable for investors over the last year : 45.55 vs. RNWAX (20.59). BEMCX return over 5 years is better than : 66.67 vs. RNWAX (9.71).
BEMCXRNWAXBEMCX / RNWAX
Total Expense Ratio2.071.66125%
Annual Report Gross Expense Ratio2.071.66125%
Fund Existence13 years24 years-
Gain YTD19.51413.903140%
Front LoadN/AN/A-
Min. Initial Investment25002501,000%
Min. Initial Investment IRAN/AN/A-
Net Assets1.32B90.9B1%
Annual Yield % from dividends1.310.49269%
Returns for 1 year45.5520.59221%
Returns for 3 years92.6146.08201%
Returns for 5 years66.679.71687%
Returns for 10 years129.43112.99115%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FBDIX189.03N/A
N/A
Franklin Biotechnology Discovery A
POMIX77.59N/A
N/A
T. Rowe Price Total Equity Market Idx
TPYYX8.52N/A
N/A
Touchstone Sands Capital Intl Gr Eq Y
VWNDX23.48N/A
N/A
Vanguard Windsor Investor Shares
FACSX57.32N/A
N/A
Nuveen Mid Cap Value Opportunities C